Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
NCT01853319
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Colorectal Neoplasms
Interventions
DRUG:
Regorafenib (Stivarga, BAY73- 4506)
Sponsor
Bayer